Library Screening

 

High-quality library collections offered by Proteros in collaboration with Enamine for immediate screening and seamless post-screening processes

  • PAINS-free screening libraries [no pan-assay interference compounds] designed by deselection of reactive compounds and unfavorable physicochemical properties
  • All libraries Ro3 or Ro5 compliant
  • Proteros hand-selected compounds/fragments from Enamine
  • Hit expansion into full-range of available Enamine compounds
  • Fast synthesis of hit analogues at Enamine (building blocks available)
  • Easy and cost-efficient access to high quality screening libraries
  • Rapid transition into Proteros structural biology platform

  • Fast HTS follow up using:
    • Reporter Displacement Assay (RDA)
    • Enzymatic Assays
    • TSA
    • SPR
    • MST
    • nanoDSF
    • nanoBRET

FIND A gallery assay

Proteins, Structures and Assays

VIEW ALL GALLERY PRODUCTS

FRAGMENT LIBRARY

3k Proteros hand-selected fragments

  • Ro3 compliant, MW 160- 300 g/mol, solubility checked
  • High diversity, max Tanimoto similarity of 0.66
  • High concentration collection (100 mM DMSO stock concentration -> up to 1 mM screening concentration)
  • Application: Fragment screening

RANGE FINDER LIBRARY

Fragment enriched 41k small molecules library

  • Fragment enriched (25% MW < 300 g/mol
  • Sorted by size: 10,000 Fragments can be screened separately
  • High sp3 fraction, average sp3 fraction = 0.42
  • Applications: Combination of fragment and small molecule screen
  • Screen of smaller library with high hit rates

SMALL MOLECULE LIBRARY

150k high quality small molecules

  • High diversity
  • Specific clustering concept (23,598 clusters, mean cluster size = 6)
  • Additional cluster members available by expansion into full range of Enamine compounds
  • Application: HTS

RANGE FINDER + SMALL MOLECULE LIBRARY

191k high quality small molecules (fragment enriched)

  • Combination of range finder and small molecule diversity library
  • Application: HTS

Proteros Statistics

0

years unlocking technically demanding targets

+0

Pharma and biotech partners

+0

Protein structures elucidated